Detalhe da pesquisa
1.
Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma.
Haematologica
; 106(8): 2224-2232, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32675228
2.
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
Eur J Nucl Med Mol Imaging
; 48(11): 3550-3559, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33928400
3.
VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma.
Eur J Haematol
; 106(1): 100-104, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32997825
4.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet
; 394(10216): 2271-2281, 2019 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31868632
5.
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
Blood
; 131(18): 2060-2064, 2018 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29475959
6.
Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma.
Blood
; 132(26): 2744-2753, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249786
7.
Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS/multiple myeloma.
Br J Haematol
; 184(3): 384-391, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30450574
8.
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
Br J Haematol
; 184(5): 760-768, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30520013
9.
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.
Br J Haematol
; 185(1): 42-52, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30592027
10.
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.
Biol Blood Marrow Transplant
; 24(6): 1172-1179, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29605716
11.
Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
Cancer Immunol Immunother
; 67(11): 1709-1718, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30132083
12.
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Blood
; 127(11): 1410-6, 2016 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755709
13.
Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation.
Blood
; 128(26): 3169-3176, 2016 12 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27811019
14.
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.
Haematologica
; 108(10): 2844-2849, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815369
15.
Rapid reconstitution of CMV-specific T-cells after stem-cell transplantation.
Eur J Haematol
; 101(1): 38-47, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29652096
16.
TP53 mutation and survival in aggressive B cell lymphoma.
Int J Cancer
; 141(7): 1381-1388, 2017 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28614910
17.
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Br J Haematol
; 179(3): 410-420, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28990173
18.
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Br J Haematol
; 179(4): 586-597, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961309
19.
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
Haematologica
; 102(11): 1913-1922, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28935843
20.
Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.
Haematologica
; 102(8): 1413-1423, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28411252